Early Access Program Results From Turkey and a Literature Review on Daratumumab Monotherapy Among Heavily Pretreated Patients With Relapsed/Refractory Myeloma


BEKSAÇ M., Aydin Y. , GÖKER H., Turgut M., Besisik S. K. , Cagirgan S., ...Daha Fazla

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, cilt.20, sa.8, 2020 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 20 Konu: 8
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1016/j.clml.2020.02.017
  • Dergi Adı: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA

Özet

The present study investigated the efficacy and safety profile of daratumumab monotherapy in 42 patients with relapsed refractory multiple myeloma through a Turkish early access program. The current findings have confirmed the efficacy of daratumumab monotherapy in heavily pretreated patients with refractory multiple myeloma because of the deep and durable responses and favorable safety and tolerability profile.